Full Sail Capital LLC Invests $533,000 in AstraZeneca plc (NYSE:AZN)

Full Sail Capital LLC acquired a new position in shares of AstraZeneca plc (NYSE:AZN) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,191 shares of the company’s stock, valued at approximately $533,000.

Several other large investors also recently bought and sold shares of the stock. FMR LLC boosted its position in AstraZeneca by 59.6% in the 4th quarter. FMR LLC now owns 56,373,971 shares of the company’s stock valued at $2,141,084,000 after buying an additional 21,048,181 shares during the period. Jennison Associates LLC boosted its position in AstraZeneca by 15.2% in the 4th quarter. Jennison Associates LLC now owns 45,796,787 shares of the company’s stock valued at $1,739,362,000 after buying an additional 6,052,483 shares during the period. OppenheimerFunds Inc. boosted its position in AstraZeneca by 141.3% in the 1st quarter. OppenheimerFunds Inc. now owns 4,105,290 shares of the company’s stock valued at $165,977,000 after buying an additional 2,403,920 shares during the period. GQG Partners LLC boosted its position in AstraZeneca by 72.0% in the 1st quarter. GQG Partners LLC now owns 5,155,269 shares of the company’s stock valued at $207,823,000 after buying an additional 2,157,252 shares during the period. Finally, Neuberger Berman Group LLC boosted its position in AstraZeneca by 68.5% in the 1st quarter. Neuberger Berman Group LLC now owns 1,544,029 shares of the company’s stock valued at $62,425,000 after buying an additional 627,941 shares during the period. 18.79% of the stock is owned by hedge funds and other institutional investors.

AZN has been the subject of several recent research reports. Zacks Investment Research raised shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Thursday, April 4th. Deutsche Bank reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, February 26th. Main First Bank reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 19th. Pareto Securities raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, April 29th. Finally, ValuEngine cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.29.

Shares of AZN traded down $0.24 during midday trading on Friday, reaching $39.67. The stock had a trading volume of 1,477,841 shares, compared to its average volume of 2,728,933. AstraZeneca plc has a 1-year low of $34.38 and a 1-year high of $43.29. The firm has a market capitalization of $100.48 billion, a price-to-earnings ratio of 11.47, a PEG ratio of 1.22 and a beta of 0.47. The company has a current ratio of 0.75, a quick ratio of 0.58 and a debt-to-equity ratio of 1.48.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.02. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. The business had revenue of $5.47 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period last year, the business earned $0.48 EPS. The company’s revenue was up 9.6% on a year-over-year basis. On average, analysts predict that AstraZeneca plc will post 1.78 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Full Sail Capital LLC Invests $533,000 in AstraZeneca plc (NYSE:AZN)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/06/16/full-sail-capital-llc-invests-533000-in-astrazeneca-plc-nyseazn.html.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: How a Put Option Works

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.